Legal Action Initiated Against Regeneron Pharmaceuticals Amid Securities Fraud Claims
A significant legal matter has arisen for investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), as the Pomerantz Law Firm has officially announced the initiation of a class action lawsuit against the company. This legal action stems from concerns over potential securities fraud and other unlawful business practices that were allegedly engaged in by Regeneron and certain key officers and directors. Investors who have suffered financial losses due to their holdings in Regeneron are encouraged to take action.
Pomerantz LLP has set a deadline of September 14, 2026, for affected investors to contact their offices if they wish to be appointed as Lead Plaintiff in this class action. Interested investors are advised to reach out to Danielle Peyton via email at [email protected] or by phone at 646-581-9980 (toll-free number: 888.4-POMLAW, Ext. 7980). To facilitate the process, those who inquire by email should include their mailing address, phone number, and the details of their Regeneron shares acquired during the specified Class Period.
The class action lawsuit highlights crucial events that may have affected the stock value of Regeneron. Notably, during the earnings call on April 29, 2026, the company disclosed alterations to its Phase III Fianlimab-Libtayo Study, which expanded the criteria for patient analysis concerning progression-free survival. The immediate aftermath of this announcement saw Regeneron's stock price plummet by $45.41, marking a 6.21% decline to close at $686.36 per share on the same day.
Further exacerbating the situation, on May 15, 2026, Regeneron disclosed information that the Phase 3 Trial of Fianlimab did not reach a statistically significant improvement for its primary endpoint of progression-free survival. This revelation triggered an even steeper drop in stock price, with shares falling by $68.57, or 9.82%, culminating at $629.68 per share by May 16, 2026.
As one of the leading firms in corporate, securities, and antitrust class litigation, Pomerantz has a long-standing history of advocating for the rights of victims affected by securities fraud and corporate misconduct. Established over 85 years ago by the late Abraham L. Pomerantz—who is recognized as a pioneering figure in the realm of securities class action—the firm has successfully recovered millions of dollars in damages for its clients over the years. Their commitment continues as they urge affected investors of Regeneron to ascertain their eligibility for the legal proceedings aimed at redressing financial grievances.
For those considering participation, more information regarding the class action lawsuit is available at Pomerantz's website (www.pomerantzlaw.com), where the official Complaint can also be accessed. As this situation continues to develop, Regeneron investors need to remain vigilant regarding their rights and potential actions they can take amid these pressing legal challenges.
Pomerantz LLP has set a deadline of September 14, 2026, for affected investors to contact their offices if they wish to be appointed as Lead Plaintiff in this class action. Interested investors are advised to reach out to Danielle Peyton via email at [email protected] or by phone at 646-581-9980 (toll-free number: 888.4-POMLAW, Ext. 7980). To facilitate the process, those who inquire by email should include their mailing address, phone number, and the details of their Regeneron shares acquired during the specified Class Period.
The class action lawsuit highlights crucial events that may have affected the stock value of Regeneron. Notably, during the earnings call on April 29, 2026, the company disclosed alterations to its Phase III Fianlimab-Libtayo Study, which expanded the criteria for patient analysis concerning progression-free survival. The immediate aftermath of this announcement saw Regeneron's stock price plummet by $45.41, marking a 6.21% decline to close at $686.36 per share on the same day.
Further exacerbating the situation, on May 15, 2026, Regeneron disclosed information that the Phase 3 Trial of Fianlimab did not reach a statistically significant improvement for its primary endpoint of progression-free survival. This revelation triggered an even steeper drop in stock price, with shares falling by $68.57, or 9.82%, culminating at $629.68 per share by May 16, 2026.
As one of the leading firms in corporate, securities, and antitrust class litigation, Pomerantz has a long-standing history of advocating for the rights of victims affected by securities fraud and corporate misconduct. Established over 85 years ago by the late Abraham L. Pomerantz—who is recognized as a pioneering figure in the realm of securities class action—the firm has successfully recovered millions of dollars in damages for its clients over the years. Their commitment continues as they urge affected investors of Regeneron to ascertain their eligibility for the legal proceedings aimed at redressing financial grievances.
For those considering participation, more information regarding the class action lawsuit is available at Pomerantz's website (www.pomerantzlaw.com), where the official Complaint can also be accessed. As this situation continues to develop, Regeneron investors need to remain vigilant regarding their rights and potential actions they can take amid these pressing legal challenges.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.